Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cross-barrier targeted drug delivery system for lesions, drug-carrier system and host cell system

A technology of drug delivery system and carrier system, applied in the field of drug delivery system and host cell system, can solve the problems of mutation and immune response, low transfection efficiency, poor biocompatibility, etc., and achieve good biocompatibility with target cells. Specificity, increase targeting efficiency, increase the effect of flexibility

Inactive Publication Date: 2019-03-26
BEIJING DIRECTION BIOTECH CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Viral vectors have high transfection efficiency, but they have great safety problems, which may cause mutations and immune reactions; while non-viral vectors such as polymers, liposomes, and inorganic nanoparticles, which have been studied more currently, have problems. Low transfection efficiency, poor biocompatibility and other shortcomings, so it is necessary to find a more suitable carrier

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cross-barrier targeted drug delivery system for lesions, drug-carrier system and host cell system
  • Cross-barrier targeted drug delivery system for lesions, drug-carrier system and host cell system
  • Cross-barrier targeted drug delivery system for lesions, drug-carrier system and host cell system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Expression and purification of HBc VLPs: Streak or spread the Escherichia coli modified by the target gene on a solid medium, culture it upside down at 37°C overnight, pick a single colony and expand it in 2.5% LB medium until the OD600 reaches 0.6 At −0.8, 0.1 mM IPTG (volume ratio IPTG:LB medium=1:10000) was added to induce culture at 18° C. for 18 h. After the induction, the bacterial liquid was collected, centrifuged at 4000 rpm for 12 min at 4°C, the supernatant was discarded, and the precipitate was collected. The pellet was resuspended with Tris buffer (10 mM Tris-HCl, 0.5% (v / v) Triton-X-100), and the resuspended solution was ultrasonically disrupted until the bacterial solution was not drawn, and the ultrasonic power was 50%. Centrifuge the crushed cells at 4°C and 12000rpm for 30min, collect the supernatant, and slowly add saturated (NH4) 2 SO 4 solution, saturated (NH 4 ) 2 SO 4 The solution accounts for 30% to 40% of the total volume, and the stirring i...

Embodiment 2

[0058] U87 cells were seeded in 96-well plates at a concentration of 5000 cells per well. 100 μL of PTX carrier solution was added to each well, and there were three groups in total: PTX group, PTX@TGN-RGD-HBc VLPs group, and PTX@TGN-RGD-HBc VLPs synergistic siRNA@TGN-RGD-HBc VLPs group (the concentration of PTX was 0.001, 0.01, 0.1, 1, 10 μg / mL). After incubation for 24 hours, discard the supernatant, add 100 μL MTT (5 mg / mL) solution and incubate for 4 hours, discard the supernatant, add 150 μL DMSO, shake on a shaker at 37°C for 30 minutes, and measure the OD value at 490 nm. The result is as figure 2 It was shown that at low concentrations of PTX, the killing effect of the PTX-loaded targeted drug group (PTX@TGN-RGD-HBc VLPs) on cells was not much different from that of the free drug group (PTX), while the synergistic drug group (PTX@TGN-RGD- RGD-HBc VLPs+YAP-siRNA@TGN-RGD-HBc VLPs) showed obvious killing effect. At high concentration, both PTX-loaded targeted drug grou...

Embodiment 3

[0060] An orthotopic glioma model bearing U87 cells was established, and TGN-RGD-HBc VLPs and non-targeting VLPs (HBc-183VLPs) were labeled with Cy5.5, administered through tail vein injection, and the live fluorescence of mice was observed at different time points Distribution. The result is as image 3 As shown, for the pictures at the same time point, the left mouse is the normal saline group, the middle mouse is the non-targeted VLPs group, and the right mouse is the double-targeted VLPs group. according to image 3 The results showed that the distribution of dual-targeted VLPs in the brain was significantly better than that of non-targeted VLPs.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a cross-barrier targeted drug delivery system for lesions, a drug-carrier system and a host cell system. The drug delivery system comprises cross-barrier virus-like particlesand lesion-targeting virus-like particles, wherein the cross-barrier virus-like particles carry cross-barrier signals, and the lesion-targeting virus-like particles carry lesion-targeting signals. Thecross-barrier virus-like particles and the lesion-targeting virus-like particles are capable of performing self-assembly to form heteropoly virus-like particles. The drug delivery system has the dualfunctions of cross-barrier and targeted transportation to the lesions, and meanwhile, the virus-like particles have the advantages of safety and high transportation efficiency.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a drug delivery system, a carrier system and a host cell system for cross-barrier targeting lesions. Background technique [0002] Drugs usually need to be delivered to the lesion at a certain speed and concentration to maximize the curative effect and minimize side effects, so that the treatment is considered effective. However, there are many natural barriers in the process of drug delivery and targeted distribution, making the originally promising drugs ineffective or ineffective. [0003] Common natural barriers that affect drug delivery include the endothelial cell barrier, including the blood-brain barrier, blood-ocular barrier, blood-milk barrier, blood-testis barrier, blood-ovarian barrier, and blood-placental barrier, and mucus barriers, including the gastrointestinal mucosal barrier, Respiratory mucosal barrier or cervical mucosal barrier. [0004] Taking th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/87A61K47/42
CPCA61K47/42C12N15/87
Inventor 任明毕胜利张利平曹健荣
Owner BEIJING DIRECTION BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com